[18F]fluoro-β-fluoromethylene-m-tyrosine derivatives show stereo, geometrical, and regio specificities as in vivo central dopaminergic probes in monkeys

Nuclear Medicine and Biology

Volumn 26, Issue 4, 1999, Pages 365-370

  Huang, S C ^a   Quintana, Javier ^a   Satyamurthy, N ^a   Lacan, Goran ^a   Yu, Dan Chu ^a   Phelps, Michael E ^a   Barrio, Jorge R ^a  

^a Division of Nuclear Medicine   (United States)

Author keywords

Fluoromethylene m tyrosine; Dopaminergic system; Monoamine oxidase inhibitor; PET

Indexed keywords

AROMATIC LEVO AMINO ACID DECARBOXYLASE; BETA FLUOROMETHYLENE META TYROSINE; BETA FLUOROMETHYLENE META TYROSINE DERIVATIVE; FLUORINE 18; UNCLASSIFIED DRUG; BETA FLUOROMETHYLENE 3 TYROSINE; BETA-FLUOROMETHYLENE-3-TYROSINE; DIAGNOSTIC AGENT; DOPAMINE; DRUG DERIVATIVE; FLUORINE; MONOAMINE OXIDASE INHIBITOR; TYROSINE;

ANIMAL EXPERIMENT; ARTICLE; BLOOD BRAIN BARRIER; DOPAMINERGIC SYSTEM; DRUG STRUCTURE; DRUG SYNTHESIS; FLUORINATION; ISOTOPE LABELING; MONKEY; NONHUMAN; POSITRON EMISSION TOMOGRAPHY; STEREOSPECIFICITY; ANIMAL; BRAIN; CERCOPITHECUS; CHEMISTRY; COMPUTER ASSISTED EMISSION TOMOGRAPHY; METABOLISM; PHYSIOLOGY; STEREOISOMERISM; STRUCTURE ACTIVITY RELATION;

ANIMALS; BLOOD-BRAIN BARRIER; BRAIN; CERCOPITHECUS AETHIOPS; DOPAMINE; FLUORINE RADIOISOTOPES; MONOAMINE OXIDASE INHIBITORS; STEREOISOMERISM; STRUCTURE-ACTIVITY RELATIONSHIP; TOMOGRAPHY, EMISSION-COMPUTED; TYROSINE;

EID: 0032589060     PISSN: 09698051     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0969-8051(99)00008-6     Document Type: Article

References (30)

1. Barrio J.R., Huang S.-C., Phelps M.E. Biological imaging and the molecular basis of dopaminergic diseases. Biochem. Pharmacol. 54:1997;341-348.
2. Barrio J.R., Huang S.-C., Yu D.-C., Melega W.P., Quintana J., Cherry S.R., Jacobson A., Namavari M., Satyamurthy N., Phelps M.E. Radiofluorinated L-m-tyrosines New in vivo probes for central dopamine biochemistry . J. Cereb. Blood Flow Metab. 16:1996;667-678.
3. Benedetti M.S., Dostert P. Monoamine oxidase, brain aging and degenerative diseases. Biochem. Pharmacol. 38:1989;555-561.
4. Calne D.B., Langston J.W., Martin W.R.W., Stoessl A.J., Ruth T.J., Adam M.J., Pate B.D., Schulzer M. Positron emission tomography after MPTP Observations relating to the cause of Parkinson's disease . Nature. 317:1985;246-248.
5. 18F-fluorodopa in the hooded rat. Biochem. Pharmacol. 37:1988;247-250.
6. 18F]fluoro-β-fluoromethylene-m-tyrosine. Brain Res. 597:1992;151-154.
7. Fowler C.J., Callingham B.A., Mantle T.J., Tipton K.F. Monoamine oxidase A and B A useful concept? Biochem. Pharmacol. 27:1978;97-101.
8. 11C-labeled suicide inactivators and PET. Science. 235:1987;481-485.
9. Hargreaves K.M., Pardridge W.M. Neutral amino acid transport at the human blood-brain barrier. J. Biol. Chem. 263:1988;19392-19397.
10. Huang S.-C., Barrio J.R., Yu D.-C., Chen B.C., Grafton S.T., Melega W.P., Hoffman J.M., Satyamurthy N., Mazziotta J.C., Phelps M.E. Modeling approach for separating blood time-activity curves in positron emission tomographic studies. Phys. Med. Biol. 36:1991;749-761.
11. Huang S.-C., Stout D.B., Yee R., Satyamurthy N., Barrio J.R. Distribution volume of radiolabeled large neutral amino acid in brain tissue. J. Cereb. Blood Flow Metab. 18:1998;1288-1293.
12. Huang S.-C., Yu D.-C., Barrio J.R., Grafton S.T., Melega W.P., Hoffman J.M., Satyamurthy N., Mazziotta J.C., Phelps M.E. Kinetics and modeling of 6-[F-18]fluoro-L-DOPA in human positron emission tomographic studies. J. Cereb. Blood Flow Metab. 11:1991;898-913.
13. Katz I.R. Inhibition of 3,4-dihydroxy-L-phenylalanine decarboxylase in rat striatal synaptosomes by amino acids interacting with substrate transport. Biochim. Biophys. Acta. 600:1980;195-204.
14. Lacan G., Satyamurthy N., Barrio J.R. (E) and (Z)-β-fluoromethylene-m-tyrosines Resolution and determination of configuration . Tetrahedron: Asymmetry. 6:1995;525-536.
15. Lacan G., Satyamurthy N., Barrio J.R. Fluorination of (E)-β-(fluoromethylene)-m-tyrosine Regioselective synthesis of 4-fluoro-(E)-β-(fluoromethylene)-m-tyrosine . J. Org. Chem. 60:1995;227-234.
16. Lacan G., Satyamurthy N., Barrio J.R. (Z)-β-Fluoromethylene-m-tyrosine Synthesis, crystal structure and fluorination . J. Fluorine Chem. 74:1995;211-219.
17. 18F]fluoro-β-fluoromethylene-m-tyrosine derivatives In vivo probes of central dopaminergic function . Nucl. Med. Biol. 26:1999;359-363.
18. McDonald I.A., Lacoste J.M., Bey P., Wagner J., Zreika M., Palfreyman M.G. Dual enzyme-activated irreversible inhibition of monoamino oxidase. Bioorg. Chem. 14:1986;103-118.
19. Melega W.P., Grafton S.T., Huang S.-C., Satyamurthy N., Phelps M.E., Barrio J.R. L-6-[F-18]Fluoro-DOPA metabolism in monkeys and humans Biochemical parameters for the formulation of tracer kinetic models for positron emission tomography . J. Cereb. Blood Flow Metab. 11:1991;890-897.
20. Melega W.P., Luxen A., Perlmutter M.M., Nissenson H.K., Phelps M.E., Barrio J.R. Comparative in vivo metabolism of 6-[F-18]fluoro-L-DOPA and [H-3]L-DOPA in rats. Biochem. Pharmacol. 39:1990;1853-1860.
21. 18F]Fluoro-β-fluoromethylene-m-tyrosine analogs, potential PET agents for presynaptic dopamine terminals Synthesis and spectroscopic characterization . Appl. Radiat. Isot. 43:1992;969-977.
22. Oldendorf W.H. Brain uptake of radiolabeled amino acids, amines, and hexoses after arterial injection. Am. J. Physiol. 221:1971;1629-1639.
23. Palfreyman M.G., Bey P., Sjoerdsma A. Enzyme-activated/mechanism-based inhibitors. Essays Biochem. 23:1987;28-81.
24. Palfreyman M.G., McDonald L.A., Bey P., Schechter P.J., Sjoerdsma A. Design and early clinical evaluation of selective inhibitors of monoamine oxidase. Prog. Neuro-Psychopharmacol. Biol. Psychiatr. 12:1988;967-987.
25. Palfreyman M.G., McDonald I.A., Fozard J.R., Mely Y., Sleight A.J., Zreika M., Wagner J., Bey P., Lewis P.J. Inhibition of monoamine oxidase selectively in brain monoamine nerves using the bioprecursor (E)-β-fluoromethylene-m-tyrosine (MDL 72394), a substrate for aromatic L-amino acid decarboxylase. J. Neurochem. 45:1985;1850-1860.
26. Pardridge W.M. Kinetics of competitive inhibition of neutral amino acid transport across the blood-brain-barrier. J. Neurochem. 28:1977;103-108.
27. Patlak C.S., Blasberg R.G., Fenstermacher J.D. Graphical evaluation of blood-to-brain transfer constants from multiple-time uptake data. J. Cereb. Blood Flow Metab. 3:1983;1-7.
28. Smith Q.R., Momma S., Aoyagi M., Rapoport S.I. Kinetics of neutral amino acid transport across the blood-brain barrier. J. Neurochem. 49:1987;1651-1658.
29. Stout D. B., Huang S. -C., Melega W. P., Raleigh M., Phelps M. E. and Barrio J. R. (1998) Effects of plasma large neutral amino acid on cerebral FDOPA uptake. J. Cereb. Blood Flow Metab. 18, 43-31.
30. Youdim M.B.H., Finberg J.P.M. Implications of MAO-A and MAO-B inhibition for antidepressant therapy. Mod. Probl. Pharmacopsychiatr. 19:1983;63-74.